Clinic
Chca Bayshore LP
Chca Bayshore LP was paid $46.89M by Medicaid between Feb 2020 and Dec 2024, across 99 billing codes. Its largest line is 99284, emergency room visit (serious) — 58% of everything it billed.
33Billing provider infoCHCA BAYSHORE LP
PASADENA, TX 77504
PASADENA, TX 77504
33aNPI1174576698assigned 05/18/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$46.89M
24GClaims473,212
24DCodes billed99
24AFirst – last monthFeb 2020 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#10 of 320
Median peer was paid$205K
This provider vs. median229×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 11,578 | $1.81M | |
| 2021 | 97,762 | $11.69M | |
| 2022 | 143,782 | $12.21M | |
| 2023 | 150,675 | $14.64M | |
| 2024incomplete | 69,415 | $6.54M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 58% | 26,210 | 25,059 | $27.32M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 65,804 | 64,184 | $9.21M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.1% | 10,437 | 10,277 | $1.48M |
| 87400 | 2.1% | 39,640 | 38,666 | $962K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.9% | 30,419 | 29,916 | $887K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.6% | 10,552 | 7,288 | $739K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 4,087 | 3,864 | $610K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13,988 | 13,489 | $409K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 15,990 | 15,722 | $408K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,121 | 12,551 | $401K |
| 81002 | <1% | 14,844 | 9,551 | $358K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,455 | 6,038 | $352K |
87 more codes
| 85027 | <1% | 35,620 | $350K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,033 | $329K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 24,647 | $304K |
| 71045 | Radiologic examination, chest; single view | <1% | 14,383 | $303K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,051 | $241K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 22,529 | $232K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,052 | $219K |
| 93975 | <1% | 793 | $157K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,243 | $119K |
| 86780 | <1% | 3,025 | $117K | |
| 81001 | <1% | 28,988 | $92K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,069 | $90K |
| 80076 | <1% | 10,840 | $87K | |
| 87420 | <1% | 7,152 | $79K | |
| 76801 | <1% | 749 | $72K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,111 | $72K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,876 | $71K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,546 | $68K |
| 86701 | <1% | 906 | $58K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 904 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,323 | $51K |
| 83690 | <1% | 9,041 | $46K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,775 | $45K |
| 80053 | Comprehensive metabolic panel | <1% | 3,877 | $44K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 440 | $36K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 298 | $36K |
| 84484 | <1% | 3,788 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 757 | $25K |
| 86803 | <1% | 751 | $25K | |
| 84703 | <1% | 4,872 | $24K | |
| 88160 | <1% | 564 | $22K | |
| 87340 | <1% | 977 | $21K | |
| 86850 | <1% | 276 | $20K | |
| 82947 | <1% | 640 | $19K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 246 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 246 | $17K |
| 84702 | <1% | 1,418 | $16K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,552 | $16K |
| 81025 | <1% | 2,167 | $14K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 245 | $14K |
| 86762 | <1% | 145 | $9K | |
| 90656 | <1% | 82 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 448 | $7K |
| 87070 | <1% | 975 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 248 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,432 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,161 | $6K |
| 86900 | <1% | 1,422 | $6K | |
| 86901 | <1% | 1,421 | $6K | |
| 90715 | <1% | 27 | $4K | |
| 82248 | <1% | 1,726 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 38 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $3K |
| 83880 | <1% | 283 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 267 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 13 | $3K |
| 74018 | <1% | 99 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 25 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 138 | $2K |
| 82105 | <1% | 36 | $2K | |
| 87653 | <1% | 29 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $2K |
| 86787 | <1% | 26 | $1K | |
| 84030 | <1% | 225 | $1K | |
| 83520 | <1% | 27 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 83 | $969.02 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 513 | $951.31 |
| 83020 | <1% | 14 | $908.15 | |
| 59430 | <1% | 12 | $902.78 | |
| 83735 | <1% | 216 | $676.84 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 33 | $578.41 |
| 82247 | <1% | 79 | $420.72 | |
| 80061 | Lipid panel | <1% | 92 | $368.26 |
| 87040 | <1% | 62 | $359.47 | |
| 85610 | <1% | 366 | $271.30 | |
| 85730 | <1% | 156 | $186.28 | |
| 81003 | <1% | 76 | $159.16 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 32 | $129.66 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 355 | $108.93 |
| 99385 | <1% | 27 | $93.47 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 49 | $53.57 |
| 87186 | <1% | 13 | $29.08 | |
| 85379 | <1% | 18 | $25.65 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 69 | $20.40 |
| A9270 | Non-covered item or service | 0% | 1,114 | $0.00 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 68 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 92 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMAGOULAS, DEMETRI (CFO)